126 related articles for article (PubMed ID: 8832699)
21. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody.
Foulon CF; Reist CJ; Bigner DD; Zalutsky MR
Cancer Res; 2000 Aug; 60(16):4453-60. PubMed ID: 10969792
[TBL] [Abstract][Full Text] [Related]
22. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report.
Bigner DD; Brown M; Coleman RE; Friedman AH; Friedman HS; McLendon RE; Bigner SH; Zhao XG; Wikstrand CJ; Pegram CN
J Neurooncol; 1995; 24(1):109-22. PubMed ID: 8523067
[TBL] [Abstract][Full Text] [Related]
23. Comparative localization of glioma-reactive monoclonal antibodies in vivo in an athymic mouse human glioma xenograft model.
Wikstrand CJ; McLendon RE; Carrel S; Kemshead JT; Mach JP; Coakham HB; de Tribolet N; Bullard DE; Zalutsky MR; Bigner DD
J Neuroimmunol; 1987 May; 15(1):37-56. PubMed ID: 3571486
[TBL] [Abstract][Full Text] [Related]
24. Catabolism of radioiodinated murine monoclonal antibody F(ab')2 fragment labeled using N-succinimidyl 3-iodobenzoate and Iodogen methods.
Garg PK; Alston KL; Zalutsky MR
Bioconjug Chem; 1995; 6(4):493-501. PubMed ID: 7578370
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.
Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; Herndon JE; Cokgor I; McLendon RE; Pegram CN; Provenzale JM; Quinn JA; Rich JN; Regalado LV; Sampson JH; Shafman TD; Wikstrand CJ; Wong TZ; Zhao XG; Zalutsky MR; Bigner DD
J Clin Oncol; 2002 Mar; 20(5):1389-97. PubMed ID: 11870184
[TBL] [Abstract][Full Text] [Related]
26. Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance.
Shankar S; Vaidyanathan G; Kuan CT; Bigner DD; Zalutsky MR
Nucl Med Biol; 2006 Jan; 33(1):101-10. PubMed ID: 16459265
[TBL] [Abstract][Full Text] [Related]
27. Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma.
Schold SC; Zalutsky MR; Coleman RE; Glantz MJ; Friedman AH; Jaszczak RJ; Bigner SH; Bigner DD
Invest Radiol; 1993 Jun; 28(6):488-96. PubMed ID: 7686539
[TBL] [Abstract][Full Text] [Related]
28. Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study.
Akabani G; Reardon DA; Coleman RE; Wong TZ; Metzler SD; Bowsher JE; Barboriak DP; Provenzale JM; Greer KL; DeLong D; Friedman HS; Friedman AH; Zhao XG; Pegram CN; McLendon RE; Bigner DD; Zalutsky MR
J Nucl Med; 2005 Jun; 46(6):1042-51. PubMed ID: 15937318
[TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent.
Reist CJ; Batra SK; Pegram CN; Bigner DD; Zalutsky MR
Nucl Med Biol; 1997 Oct; 24(7):639-47. PubMed ID: 9352535
[TBL] [Abstract][Full Text] [Related]
30. Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.
Reardon DA; Quinn JA; Akabani G; Coleman RE; Friedman AH; Friedman HS; Herndon JE; McLendon RE; Pegram CN; Provenzale JM; Dowell JM; Rich JN; Vredenburgh JJ; Desjardins A; Sampson JH; Gururangan S; Wong TZ; Badruddoja MA; Zhao XG; Bigner DD; Zalutsky MR
J Nucl Med; 2006 Jun; 47(6):912-8. PubMed ID: 16741299
[TBL] [Abstract][Full Text] [Related]
31. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.
Cokgor I; Akabani G; Kuan CT; Friedman HS; Friedman AH; Coleman RE; McLendon RE; Bigner SH; Zhao XG; Garcia-Turner AM; Pegram CN; Wikstrand CJ; Shafman TD; Herndon JE; Provenzale JM; Zalutsky MR; Bigner DD
J Clin Oncol; 2000 Nov; 18(22):3862-72. PubMed ID: 11078500
[TBL] [Abstract][Full Text] [Related]
32. In vivo imaging of intracranial human glioma xenografts comparing specific with nonspecific radiolabeled monoclonal antibodies.
Bullard DE; Adams CJ; Coleman RE; Bigner DD
J Neurosurg; 1986 Feb; 64(2):257-62. PubMed ID: 3944636
[TBL] [Abstract][Full Text] [Related]
33. A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.
Reardon DA; Zalutsky MR; Akabani G; Coleman RE; Friedman AH; Herndon JE; McLendon RE; Pegram CN; Quinn JA; Rich JN; Vredenburgh JJ; Desjardins A; Guruangan S; Boulton S; Raynor RH; Dowell JM; Wong TZ; Zhao XG; Friedman HS; Bigner DD
Neuro Oncol; 2008 Apr; 10(2):182-9. PubMed ID: 18287339
[TBL] [Abstract][Full Text] [Related]
34. Comparison of monoclonal antibody delivery to intracranial glioma xenografts by intravenous and intracarotid administration.
Lee YS; Bullard DE; Wikstrand CJ; Zalutsky MR; Muhlbaier LH; Bigner DD
Cancer Res; 1987 Apr; 47(7):1941-6. PubMed ID: 3815382
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent.
Shankar S; Vaidyanathan G; Affleck DJ; Peixoto K; Bigner DD; Zalutsky MR
Nucl Med Biol; 2004 Oct; 31(7):909-19. PubMed ID: 15464393
[TBL] [Abstract][Full Text] [Related]
36. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
Orlova A; Wållberg H; Stone-Elander S; Tolmachev V
J Nucl Med; 2009 Mar; 50(3):417-25. PubMed ID: 19223403
[TBL] [Abstract][Full Text] [Related]
37. Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma.
Rizzieri DA; Akabani G; Zalutsky MR; Coleman RE; Metzler SD; Bowsher JE; Toaso B; Anderson E; Lagoo A; Clayton S; Pegram CN; Moore JO; Gockerman JP; DeCastro C; Gasparetto C; Chao NJ; Bigner DD
Blood; 2004 Aug; 104(3):642-8. PubMed ID: 15100153
[TBL] [Abstract][Full Text] [Related]
38. High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use.
Zalutsky MR; Zhao XG; Alston KL; Bigner D
J Nucl Med; 2001 Oct; 42(10):1508-15. PubMed ID: 11585865
[TBL] [Abstract][Full Text] [Related]
39. Labeling Monoclonal Antibody with α-emitting
Vaidyanathan G; Pozzi OR; Choi J; Zhao XG; Murphy S; Zalutsky MR
Cancer Biother Radiopharm; 2020 Sep; 35(7):511-519. PubMed ID: 32109139
[No Abstract] [Full Text] [Related]
40. Monoclonal antibody and F(ab')2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration.
Zalutsky MR; Moseley RP; Benjamin JC; Colapinto EV; Fuller GN; Coakham HP; Bigner DD
Cancer Res; 1990 Jul; 50(13):4105-10. PubMed ID: 2162252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
